CHARLESTON, S.C., Aug. 16, 2010 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP), begins collaboration with H. Keith Brown, PhD, Philadelphia College of Osteopathic Medicine, on two clinical applications using their proprietary Magnetic Resonance software tools; RevDisplay, RevColor and Rev3D.  One clinical application is for the differentiation and characterization of Intracranial Hemorrhages by Color MRI Automatic Segmentation and the other is for characterization of intracranial masses by Color MRI Automatic Segmentation. 

Led by Professor of Anatomy, H. Keith Brown, PhD, these studies will be the first of their kind to examine the use of RevMed's proprietary MRI software tools to enhance diagnostic confidence in the diagnosis of tumors, cysts, and other masses and to aid in distinguishing between older blood and new blood for concussions and other head injuries.

"To be working with the pioneer of color MRI, H. Keith Brown, PhD, on a project of this importance, means a great deal to all of us here at Revolutions Medical.  We will now begin the validation process for the use of our MRI software tools through these first of many clinical applications to be delivered through our software as a service (SAS) model.  We believe this process has the potential to add tremendous value to the company as we launch our tools into the marketplace," stated Ron Wheet, CEO, Revolutions Medical. 

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company.  Its products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. The Company also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS.  The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

For additional information about, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com

Investor Resource Center

Fact Sheet:

http://content.stockpr.com/rmcp/files/RMCP+-+Fact+Sheet+02-26-10.pdf

CEO Ron Wheet Audio Interview:

http://ir.stockpr.com/revolutionsmedical/media-center/view/33/

RevVac Demo Video:

http://revolutionsmedical.com/

To be added to the Revolutions Medical investor email list, please email Skey@revolutionsmedical.com with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook - visit http://www.facebook.com/RevMed

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements.  These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity.  We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Additional information on risks and other factors that may affect the business and financial results of Revolutions Medical Corporation can be found in the Company's periodic and other  filings with the U.S. Securities and Exchange Commission.